The severity of microvascular dysfunction due to compartment syndrome is diminished by the systemic application of co-releasing molecule-3

Journal of Orthopaedic Trauma

Volumn 28, Issue 11, 2014, Pages e263-e268

  Lawendy, Abdel Rahman ^a,b   Bihari, Aurelia ^a,b   Sanders, David W ^a,b   Potter, Richard F ^a,b   Cepinskas, Gediminas ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

CO releasing molecule 3; Compartment syndrome; Intravital video microscopy; Microvascular dysfunction

Indexed keywords

ANTIINFLAMMATORY AGENT; BISBENZIMIDE; BROMIDE; CARBON MONOXIDE; CARBON MONOXIDE RELEASING MOLECULE 3; ISOTONIC SOLUTION; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ORGANOMETALLIC COMPOUND; TRICARBONYLCHLORO(GLYCINATO)RUTHENIUM(II);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CAPILLARY; CELL COMPARTMENTALIZATION; CHEMOPROPHYLAXIS; COMPARTMENT SYNDROME; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG SYNTHESIS; EXTENSOR DIGITORUM LONGUS MUSCLE; FASCIOTOMY; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LIMB; MALE; MICROANGIOPATHY; MICROVASCULAR DYSFUNCTION; MORBIDITY; MUSCLE INJURY; MUSCLE PERFUSION; NONHUMAN; RAT; SHAM PROCEDURE; TISSUE INJURY; VIDEO MICROSCOPY; WISTAR RAT; ANIMAL; BLOOD FLOW VELOCITY; CAPILLARY PERMEABILITY; COMPARTMENT SYNDROMES; DRUG EFFECTS; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MICROVASCULATURE; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; BLOOD FLOW VELOCITY; CAPILLARIES; CAPILLARY PERMEABILITY; COMPARTMENT SYNDROMES; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICROVESSELS; ORGANOMETALLIC COMPOUNDS; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84915807694     PISSN: 08905339     EISSN: 15312291     Source Type: Journal    
DOI: 10.1097/BOT.0000000000000097     Document Type: Conference Paper

References (37)

1. Matsen FA III. Compartmental syndromes. Hosp Pract. 1980; 15:113-117.
2. Mubarak SJ, Owen CA, Hargens A.R., et al. Acute compartment syndromes: diagnosis and treatment with the aid of the wick catheter. J Bone Joint Surg Am. 1978; 60:1091-1095.
3. Whitesides TE, Haney TC, Morimoto K, et al Tissue pressure measurements as a determinant for the need of fasciotomy. Clin Orthop Relat Res. 1975; 113:43-51.
4. Matsen FA III. Compartmental syndrome. An unified concept. Clin Orthop Relat Res. 1975; 113:8-14.
5. Rorabeck CH, Clarke KM The pathophysiology of the anterior tibial compartment syndrome: an experimental investigation. J Trauma. 1978; 18:299-304.
6. Hartsock LA, O'Farrell D, Seaber AV, et al Effect of increased compartment pressure on the microcirculation of skeletal muscle. Microsurgery. 1998; 18:67-71.
7. Matsen FA III, Winquist RA, Krugmire RB Jr. Diagnosis and management of compartmental syndromes. J Bone Joint Surg Am. 1980; 62: 286-291.
8. Sheridan GW, Matsen FA An animal model of the compartmental syndrome. Clin Orthop Relat Res. 1975; 113:36-42.
9. Lawendy AR, Bihari A, Sanders D.W., et al. Compartment syndromeinduced microvascular dysfunction: an experimental rodent model. Can J Surg. 2011; 54:194-200.
10. Sadasivan KK, Carden DL, Moore M.B., et al. Neutrophil mediated microvascular injury in acute, experimental compartment syndrome. Clin Orthop Relat Res. 1997; 339:206-215.
11. Kalns J, Cox J, Baskin J., et al. Threshold model for extremity compartment syndrome in swine. J Surg Res. 2011; 167:e13-e19.
12. Ott MC, Scott JR, Bihari A, et al Inhalation of carbon monoxide prevents liver injury and inflammation following hind limb ischemia/reperfusion. FASEB J. 2005; 19:106-108.
13. Scott JR, Cukiernik MA, Ott M.C., et al. Low-dose inhaled carbon monoxide attenuates the remote intestinal inflammatory response elicited by hindlimb ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol. 2009; 296:G9-G14.
14. Hegazi RA, Rao KN, Mayle A, et al Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med. 2005; 202:1703-1713.
15. Nakao A, Kimizuka K, Stolz D.B., et al. Carbon monoxide inhalation protects rat intestinal grafts from ischemia/reperfusion injury. Am J Pathol. 2003; 163:1587-1598.
16. Mazzola S, Forni M, Albertini M., et al. Carbon monoxide pretreatment prevents respiratory derangement and ameliorates hyperacute endotoxic shock in pigs. FASEB J. 2005; 19:2045-2047.
17. Motterlini R. Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, anti-ischaemic and anti-inflammatory activities. Biochem Soc Trans. 2007; 35:1142-1146.
18. Motterlini R, Clark JE, Foresti R, et al Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ Res. 2002; 90:E17-E24.
19. Clark JE, Naughton P, Shurey S., et al. Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. Circ Res. 2003; 93:e2-e8.
20. Motterlini R, Otterbein LE The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 2010; 9:728-743.
21. Cepinskas G, Katada K, Bihari A., et al. Carbon monoxide liberated from carbon monoxide-releasing molecule CORM-2 attenuates inflammation in the liver of septic mice. Am J Physiol Gastrointest Liver Physiol. 2008; 294:G184-G191.
22. Katada K, Bihari A, Mizuguchi S., et al. Carbon monoxide liberated from CO-releasing molecule (CORM-2) attenuates ischemia/reperfusion (I/R)induced inflammation in the small intestine. Inflammation. 2010; 33:92-100.
23. Mizuguchi S, Stephen J, Bihari A., et al. CORM-3-derived CO modulates polymorphonuclear leukocyte migration across the vascular endothelium by reducing levels of cell surface-bound elastase. Am J Physiol Heart Circ Physiol. 2009; 297:H920-H929.
24. Olson SA, Glasgow RR Acute compartment syndrome in lower extremity musculoskeletal trauma. J Am Acad Orthop Surg. 2005; 13:436-444.
25. Guo Y, Stein AB, Wu W.J., et al. Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. Am J Physiol Heart Circ Physiol. 2004; 286:H1649-H1653.
26. Otterbein LE. The evolution of carbon monoxide into medicine. Respir Care. 2009; 54:925-932.
27. Forbes TL, Carson M, Harris K.A., et al. Skeletal muscle injury induced by ischemia-reperfusion. Can J Surg. 1995; 38:56-63.
28. Gute DC, Ishida T, Yarimizu K., et al. Inflammatory responses to ischemia and reperfusion in skeletal muscle. Mol Cell Biochem. 1998; 179: 169-187.
29. Kurose I, Anderson DC, Miyasaka M, et al Molecular determinants of reperfusion-induced leukocyte adhesion and vascular protein leakage. Circ Res. 1994; 74:336-343.
30. Forbes TL, Harris KA, Jamieson W.G., et al. Leukocyte activity and tissue injury following ischemia-reperfusion in skeletal muscle. Microvasc Res. 1996; 51:275-287.
31. Mizuguchi S, Capretta A, Suehiro S., et al. Carbon monoxide-releasing molecule CORM-3 suppresses vascular endothelial cell SOD-1/SOD-2 activity while up-regulating the cell surface levels of SOD-3 in a heparin-dependent manner. Free Radic Biol Med. 2010; 49:1534-1541.
32. Vadori M, Seveso M, Besenzon F., et al. In vitro and in vivo effects of the carbon monoxide-releasing molecule, CORM-3, in the xenogeneic pig-to-primate context. Xenotransplantation. 2009; 16:99-114.
33. Song H, Bergstrasser C, Rafat N., et al. The carbon monoxide releasing molecule (CORM-3) inhibits expression of vascular cell adhesion molecule-1 and E-selectin independently of haem oxygenase-1 expression. Br J Pharmacol. 2009; 157:769-780.
34. Bergstraesser C, Hoeger S, Song H., et al. Inhibition of VCAM-1 expression in endothelial cells by CORM-3: the role of the ubiquitin-proteasome system, p38, and mitochondrial respiration. Free Radic Biol Med. 2012; 52:794-802.
35. Ley K, Laudanna C, Cybulsky M.I., et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007; 7:678-689.
36. Lancel S, Hassoun SM, Favory R, et al Carbon monoxide rescues mice from lethal sepsis by supporting mitochondrial energetic metabolism and activating mitochondrial biogenesis. J Pharmacol Exp Ther. 2009; 329: 641-648.
37. Foresti R, Hammad J, Clark J.E., et al. Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. Br J Pharmacol. 2004; 142:453-460.